ECX — Epigenomics AG Balance Sheet
0.000.00%
- €0.77m
- €11.39m
Annual balance sheet for Epigenomics AG, fiscal year end - December 31st, EUR millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | R2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | — | — | — | — | — |
| Source: | ARS | ARS | ARS | ARS | ARS |
| Standards: | IFRS | IFRS | GAS | GAS | GAS |
| Status: | Final | Final | Final | Final | Final |
| Cash and Equivalents | |||||
| Short Term Investments | |||||
| Cash and Short Term Investments | 4.47 | 23 | 7.8 | 2.1 | 0.927 |
| Net Total Accounts Receivable | |||||
| Net Total Receivables | 0.401 | 0.173 | 0.051 | 0.299 | 0 |
| Total Inventory | |||||
| Prepaid Expenses | |||||
| Total Other Current Assets | |||||
| Total Current Assets | 5.47 | 23.7 | 8.12 | 2.49 | 0.971 |
| Gross Property, Plant And Equipment | |||||
| Accumulated Depreciation | |||||
| Net Property, Plant And Equipment | 1.18 | 0.891 | 0.568 | 0.003 | 0 |
| Net Intangible Assets | |||||
| Long Term Investments | |||||
| Other Long Term Assets | |||||
| Total Assets | 6.8 | 24.7 | 14 | 12.8 | 11.9 |
| Accounts Payable | |||||
| Accrued Expenses | |||||
| Notes Payable / Short Term Debt | |||||
| Current Portion of Long Term Debt / Capital Leases | |||||
| Total Other Current Liabilities | |||||
| Total Current Liabilities | 2.44 | 2.14 | 0.657 | 0.482 | 0.012 |
| Long Term Debt | |||||
| Capital Lease Obligations | |||||
| Total Long Term Debt | |||||
| Total Debt | |||||
| Total Other Liabilities | |||||
| Total Liabilities | 2.93 | 2.54 | 14 | 12.8 | 11.9 |
| Common Stock | |||||
| Additional Paid In Capital | |||||
| Retained Earnings (Accumulated Deficit) | |||||
| Other Equity | |||||
| Total Equity | 3.86 | 22.1 | 0 | 0 | 0 |
| Total Liabilities & Shareholders' Equity | 6.8 | 24.7 | 14 | 12.8 | 11.9 |
| Total Common Shares Outstanding |